Macquarie Group
TARS icon

Macquarie Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Macquarie Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-833,437
Closed -$49.5M – 1436
2025
Q3 		$49.5M Sell
833,437
-115,413
-12% -$5.68M 0.06% 424
2025
Q2 		$38.4M Buy
948,850
+56,069
+6% +$2.52M 0.05% 484
2025
Q1 		$45.9M Buy
892,781
+76,869
+9% +$3.8M 0.06% 425
2024
Q4 		$45.2M Buy
815,912
+221,034
+37% +$10M 0.05% 443
2024
Q3 		$19.6M Buy
594,878
+139,887
+31% +$3.93M 0.02% 672
2024
Q2 		$12.4M Buy
454,991
+304,991
+203% +$10.3M 0.01% 767
2024
Q1 		$5.45M Hold
150,000
– – 0.01% 945
2023
Q4 		$3.04M Hold
150,000
– – ﹤0.01% 1105
2023
Q3 		$2.67M Hold
150,000
– – ﹤0.01% 1084
2023
Q2 		$2.71M Hold
150,000
– – ﹤0.01% 1086
2023
Q1 		$1.89M Sell
150,000
-22,908
-13% -$335K ﹤0.01% 1187
2022
Q4 		$2.54M Hold
172,908
– – ﹤0.01% 1139
2022
Q3 		$2.96M Hold
172,908
– – ﹤0.01% 1113
2022
Q2 		$2.52M Buy
+172,908
New +$2.6M ﹤0.01% 1217

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Macquarie Group's TARS Position: Q4 2025 in Review

Macquarie Group sold out of Tarsus Pharmaceuticals (TARS) in Q4 2025, closing a stake of 833,437 shares — an estimated $49.5M sold.

Macquarie Group first reported a position in TARS in Q2 2022 and held it in 14 quarters. The position peaked at $49.5M in Q3 2025. 246 funds tracked by Wall St. Rank hold TARS as of Q4 2025.

  • Macquarie Group reported no remaining Tarsus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 833,437 Tarsus Pharmaceuticals shares in Q4 2025, an estimated $49.5M.
  • Macquarie Group first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 14 quarters.
  • Macquarie Group's Tarsus Pharmaceuticals position peaked at $49.5M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.